Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC)
Condition: Atrial Fibrillation (AF) Interventions: Biological: Abelacimab; Drug: Placebo Sponsor: Anthos Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials